1. A Retrospective Comparison of Docetaxel and Paclitaxel for Patients with Advanced or Recurrent Esophageal Cancer Who Previously Received Platinum-Based Chemotherapy
- Author
-
Tomoya Yokota, Motoo Nomura, Chihiro Kondo, Daisuke Takahari, Ayako Mizota, Kei Muro, Kohei Shitara, and Takashi Ura
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Esophageal Neoplasms ,Organoplatinum Compounds ,Paclitaxel ,medicine.medical_treatment ,Docetaxel ,Disease-Free Survival ,chemistry.chemical_compound ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,business.industry ,Follow up studies ,Retrospective cohort study ,General Medicine ,Middle Aged ,Esophageal cancer ,Recurrent esophageal cancer ,medicine.disease ,Antineoplastic Agents, Phytogenic ,humanities ,body regions ,chemistry ,Disease Progression ,Female ,Taxoids ,Neoplasm staging ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies ,medicine.drug - Abstract
Objective: To retrospectively compare docetaxel (DTX) with paclitaxel (PTX) with regard to efficacy and safety in advanced or recurrent esophageal cancer patients who previously received platinum-based chemotherapy. Methods: We retrospectively analyzed 124 advanced or recurrent esophageal cancer patients who had received platinum-based chemotherapy and then received DTX or PTX from April 2006 to November 2010. Results: Eighty-six patients (69.4%) received DTX and 38 patients (30.6%) received PTX monotherapy. Due to toxicity, dose reduction was needed in 36.0 and 27.8% of patients and treatment was discontinued in 10.5 and 2.6% of patients receiving DTX and PTX, respectively. The objective response (25.7 vs. 10.3%, p = 0.03) and disease control rates (60.0 vs. 34.6%, p = 0.01) were higher in the PTX group than in the DTX group, respectively. There were no significant differences in median progression-free survival (2.1 vs. 3.5 months) and overall survival (6.1 vs. 7.2 months) between the DTX and PTX groups, respectively. Grade 3–4 neutropenia (48.8 vs. 21.1%, p = 0.003) and febrile neutropenia (20.9 vs. 5.3%, p = 0.029) were more frequent in the DTX patients than in the PTX patients, respectively. Conclusion: Although the efficacy of DTX and PTX for advanced or recurrent esophageal cancer patients after platinum-based chemotherapy was not significantly different in terms of survival, PTX was a more feasible treatment. PTX provided similar efficacy to DTX with less febrile neutropenia.
- Published
- 2011